13D Filing: Lansdowne Partners and Summit Therapeutics PLC (ADR) (SMMT)

Page 5 of 8 – SEC Filing

ITEM 5.

INTEREST IN SECURITIES OF THE ISSUER.

(a – e) Regarding aggregate
beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership, see Row
13 of the cover page of each Reporting Person. Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting
Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power to dispose
of shares, see Row 9 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row 10 of the
cover page of each Reporting Person.

The transactions by the
Reporting Persons in the Shares during the past sixty days, which were open market transactions, are set forth in Exhibit B.

ITEM 6.

CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
RESPECT TO SECURITIES OF THE ISSUER.

None

ITEM 7.

MATERIAL TO BE FILED AS EXHIBITS.

Exhibit A

Exhibit B

Joint Filing Agreement

Schedule of Transactions in Shares

Follow Summit Therapeutics Inc. (NASDAQ:SMMT)